203 related articles for article (PubMed ID: 36949468)
1. The WAVE3/β-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer.
Wang W; Rana PS; Markovic V; Sossey-Alaoui K
Breast Cancer Res; 2023 Mar; 25(1):31. PubMed ID: 36949468
[TBL] [Abstract][Full Text] [Related]
2. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
3. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
4. A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple-negative breast cancer.
Sun J; Li X; Yu E; Liu J; Sun L; He Q; Lu Q
Diagn Pathol; 2021 May; 16(1):45. PubMed ID: 34006305
[TBL] [Abstract][Full Text] [Related]
5. Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells.
Taylor MA; Davuluri G; Parvani JG; Schiemann BJ; Wendt MK; Plow EF; Schiemann WP; Sossey-Alaoui K
Breast Cancer Res Treat; 2013 Nov; 142(2):341-53. PubMed ID: 24197660
[TBL] [Abstract][Full Text] [Related]
6. Integrin α9 depletion promotes β-catenin degradation to suppress triple-negative breast cancer tumor growth and metastasis.
Wang Z; Li Y; Xiao Y; Lin HP; Yang P; Humphries B; Gao T; Yang C
Int J Cancer; 2019 Nov; 145(10):2767-2780. PubMed ID: 31008533
[TBL] [Abstract][Full Text] [Related]
7. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
Shen H; Yan W; Yuan J; Wang Z; Wang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
[TBL] [Abstract][Full Text] [Related]
8. DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation.
Xiong Z; Yang L; Li N; Fu J; Liu P; Sun P; Wei W; Xie X
Clin Transl Med; 2022 Dec; 12(12):e1133. PubMed ID: 36536485
[TBL] [Abstract][Full Text] [Related]
9. Wnt signaling in triple negative breast cancer is associated with metastasis.
Dey N; Barwick BG; Moreno CS; Ordanic-Kodani M; Chen Z; Oprea-Ilies G; Tang W; Catzavelos C; Kerstann KF; Sledge GW; Abramovitz M; Bouzyk M; De P; Leyland-Jones BR
BMC Cancer; 2013 Nov; 13():537. PubMed ID: 24209998
[TBL] [Abstract][Full Text] [Related]
10. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.
Cheng S; Huang Y; Lou C; He Y; Zhang Y; Zhang Q
Cancer Biol Ther; 2019; 20(3):328-337. PubMed ID: 30336071
[TBL] [Abstract][Full Text] [Related]
11. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
[TBL] [Abstract][Full Text] [Related]
12. CircRNA_069718 promotes cell proliferation and invasion in triple-negative breast cancer by activating Wnt/β-catenin pathway.
Zhang J; Xu HD; Xing XJ; Liang ZT; Xia ZH; Zhao Y
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5315-5322. PubMed ID: 31298383
[TBL] [Abstract][Full Text] [Related]
13. Reduction of nuclear Y654-p-β-catenin expression through SH3GL2-meditated downregulation of EGFR in chemotolerance TNBC: Clinical and prognostic importance.
Islam MS; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Kumar Panda C
J Cell Physiol; 2020 Nov; 235(11):8114-8128. PubMed ID: 31960967
[TBL] [Abstract][Full Text] [Related]
14. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
15. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
[TBL] [Abstract][Full Text] [Related]
16. Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer.
Kulkarni S; Augoff K; Rivera L; McCue B; Khoury T; Groman A; Zhang L; Tian L; Sossey-Alaoui K
PLoS One; 2012; 7(8):e42895. PubMed ID: 22952619
[TBL] [Abstract][Full Text] [Related]
17. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of endoplasmic reticulum stress alleviates triple-negative breast cancer cell viability, migration, and invasion by Syntenin/SOX4/Wnt/β-catenin pathway via regulation of heat shock protein A4.
Nan J; Hu X; Guo B; Xu M; Yao Y
Bioengineered; 2022 Apr; 13(4):10564-10577. PubMed ID: 35442158
[TBL] [Abstract][Full Text] [Related]
19. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
[TBL] [Abstract][Full Text] [Related]
20. Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1α-mediated angiogenesis.
Davuluri G; Schiemann WP; Plow EF; Sossey-Alaoui K
JAKSTAT; 2014; 3(4):e1009276. PubMed ID: 26413422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
